Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells (Q39171321)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 12 May 2013

Language	Label	Description	Also known as
English	Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells	scientific article published on 12 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Takahiro Yamauchi

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Kanako Uzui

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Hiroko Shigemi

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Eiju Negoro

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Akira Yoshida

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Takanori Ueda

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

12 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

926-933

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

The cellular geography of aurora kinases

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Aurora kinases in spindle assembly and chromosome segregation

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Aurora-kinase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Mitotic drivers--inhibitors of the Aurora B Kinase

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Aurora kinases: new targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Validating Aurora B as an anti-cancer drug target.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Aurora kinases: shining lights on the therapeutic horizon?

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Therapeutic Advances in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

New trends in the standard of care for initial therapy of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

New approaches in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12164

21 January 2018

DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/CAS.12164

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39171321&oldid=1811627989"